๐๐จ๐ซ๐ญ๐ก ๐๐ฆ๐๐ซ๐ข๐๐ ๐๐ซ๐๐ง๐ฌ๐๐๐๐ญ๐ข๐จ๐ง ๐๐๐๐ ๐๐ง๐ญ๐ฌ ๐๐ง๐ ๐๐ช๐ฎ๐ข๐ฉ๐ฆ๐๐ง๐ญ ๐๐๐ซ๐ค๐๐ญ ๐๐ข๐ณ๐, ๐๐ก๐๐ซ๐ & ๐๐ซ๐จ๐ฐ๐ญ๐ก ๐๐๐ฉ๐จ๐ซ๐ญ (๐๐๐๐-๐๐๐๐)
๐๐๐ญ๐๐ข๐ฅ๐๐ ๐๐- https://lnkd.in/d2XgCzEp
The revenue trend illustrates steady growth from 2020 through 2035, with a pronounced acceleration post-2025 driven by rising investments in gene therapy, protein therapeutics, and advanced cell engineering applications. By 2025, revenue is projected to surpass 1450 million, reflecting increased product adoption and market penetration. Continued innovation and expansion into new disease areas are expected to maintain the upward trajectory, positioning North America as a global leader in transfection technologies.
Key Drivers
Rising demand for gene therapy and personalized medicine has significantly pushed investments and innovation. For instance, in June 2024, Thermo Fisher Scientific expanded its gene therapy portfolio with new transfection solutions tailored to clinical-stage manufacturing.
Strong funding for cancer and biomedical research has accelerated adoption. In July 2024, Merck KGaA announced expanded collaborations with North American academic institutions for developing advanced transfection reagents.
Key Trends
Shift towards non-viral transfection technologies such as electroporation and lipid-based methods due to safety and scalability, evidenced by Lonza Group’s launch of next-generation electroporation instruments in July 2024.
Growing integration of AI-powered platforms for precision transfection and process optimization, as demonstrated by Agilent Technologies’ AI-enabled cell engineering workflows released in August 2024.
Market Insights & Segmentation
Type (Reagents, Instruments),
Application (Biomedical Research, Therapeutic Delivery, Protein Production, Cancer Research, Gene Therapy, Others),
Distribution Channels (Direct Tenders, Retail Sales, E-commerce, Distributors, Wholesalers, Others),
Technology (Physical, Chemical, Biological, Viral-mediated, Electroporation, Lipofection),
Organization Size (Small, Medium, Large)
Key Market Companies
Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, QIAGEN, Mirus Bio LLC, MaxCyte Inc., Lonza Group, Polyplus-transfection SA, Promega Corporation, Agilent Technologies, Takara Bio Inc., Horizon Discovery, Origene Technologies, Bio-Techne, F. Hoffmann-La Roche
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ- https://lnkd.in/dg9dZUWE
๐๐๐ญ๐๐ข๐ฅ๐๐ ๐๐- https://lnkd.in/d2XgCzEp
The revenue trend illustrates steady growth from 2020 through 2035, with a pronounced acceleration post-2025 driven by rising investments in gene therapy, protein therapeutics, and advanced cell engineering applications. By 2025, revenue is projected to surpass 1450 million, reflecting increased product adoption and market penetration. Continued innovation and expansion into new disease areas are expected to maintain the upward trajectory, positioning North America as a global leader in transfection technologies.
Key Drivers
Rising demand for gene therapy and personalized medicine has significantly pushed investments and innovation. For instance, in June 2024, Thermo Fisher Scientific expanded its gene therapy portfolio with new transfection solutions tailored to clinical-stage manufacturing.
Strong funding for cancer and biomedical research has accelerated adoption. In July 2024, Merck KGaA announced expanded collaborations with North American academic institutions for developing advanced transfection reagents.
Key Trends
Shift towards non-viral transfection technologies such as electroporation and lipid-based methods due to safety and scalability, evidenced by Lonza Group’s launch of next-generation electroporation instruments in July 2024.
Growing integration of AI-powered platforms for precision transfection and process optimization, as demonstrated by Agilent Technologies’ AI-enabled cell engineering workflows released in August 2024.
Market Insights & Segmentation
Type (Reagents, Instruments),
Application (Biomedical Research, Therapeutic Delivery, Protein Production, Cancer Research, Gene Therapy, Others),
Distribution Channels (Direct Tenders, Retail Sales, E-commerce, Distributors, Wholesalers, Others),
Technology (Physical, Chemical, Biological, Viral-mediated, Electroporation, Lipofection),
Organization Size (Small, Medium, Large)
Key Market Companies
Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, QIAGEN, Mirus Bio LLC, MaxCyte Inc., Lonza Group, Polyplus-transfection SA, Promega Corporation, Agilent Technologies, Takara Bio Inc., Horizon Discovery, Origene Technologies, Bio-Techne, F. Hoffmann-La Roche
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ- https://lnkd.in/dg9dZUWE
434 Views
